These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1945 related articles for article (PubMed ID: 33942578)

  • 1. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea.
    Jeon M; Kim J; Oh CE; Lee JY
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Al Meslamani AZ; Hayajneh W; Ata OMA; Shnaigat W; AbuRuz S; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Khader K; Hakim T; Hammad FA; Al Qudah M; Asad M
    Clin Drug Investig; 2022 Oct; 42(10):813-827. PubMed ID: 35999428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.
    Kaur S; Singh A; Saini S; Rohilla L; Kaur J; Chandi A; Kaur G; Singh M; Kumar P; Soni SL; Kajal K; Naik NB; Malhotra P; Verma S; Gupta M; Devnani M; Das K; Pandav SS; Puri GD
    Indian J Med Res; 2022 Jan; 155(1):123-128. PubMed ID: 35859438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
    Li Y; Li J; Dang Y; Chen Y; Tao C
    JMIR Public Health Surveill; 2024 Jul; 10():e51007. PubMed ID: 39008362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study.
    Jose D; Dhupdale N; Cacodcar JA; Kamat U
    Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
    Ogar CK; Gilbert HN; Bloem LT; Leopold C; Bassi PU; Katagum YM; Osakwe AI; Opadeyi AO; Oreagba I; Mbo DND; Mantel-Teeuwisse AK; De Bruin ML
    Vaccine; 2024 Oct; 42(23):126196. PubMed ID: 39178765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand.
    Sirisuk W; Limvorapitak W; Lolekha P; Methaset K; Kulkantrakorn K
    Clin Neurol Neurosurg; 2023 Aug; 231():107804. PubMed ID: 37295197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
    Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
    Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
    Kamble B; Bashar MA; Mishra CP
    Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.
    Song JY; Cheong HJ; Kim SR; Lee SE; Kim SH; Noh JY; Yoon YK; Choi WS; Park DW; Sohn JW; Kim WJ; Kim MJ
    J Korean Med Sci; 2021 Apr; 36(15):e110. PubMed ID: 33876589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Kaur U; K L A; Chauhan M; Joshi A; Das A; Kansal S; Jaisawal V; Patwardhan K; Chakrabarti SS
    Drug Saf; 2022 Oct; 45(10):1099-1109. PubMed ID: 36030299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.
    Gandhi AP; Venkatesh U; Murali N
    Indian Heart J; 2023; 75(2):139-144. PubMed ID: 36863611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 98.